Emmaus Life Sciences
OTC: EMMATorrance, US · Delaware corporation
Find your way into Emmaus Life Sciences
37 people in our graph share verified history with the Emmaus Life Sciences team — schools, employers, funds. One of them is your warm intro.
Frank Buckleyunlockedknows Daniel R. Kimbell · together at UCLA (overlapped)
×7knows the team · via UCLA
×4knows the team · via Loyola Law School, Los Angeles
Emmaus Life Sciences is a pharmaceutical company that develops and commercializes Endari (prescription-grade L-glutamine oral powder), an FDA-approved treatment for sickle cell disease, and pursues additional indications such as diverticulosis. The company sells and seeks marketing authorization for its products in the United States and internationally, including the Middle East and North Africa region.
Founders & leadership
YN
Yutaka NiiharainFormer Chairman & CEO
DR
Daniel R. KimbellinFounderDaniel R. Kimbell is a patent attorney who has prosecuted over 1,000 patent applications and 1,000 trademarks across various industries, managing IP portfolios and handling in- and out-licensing deals, with expertise in intellectual property law, technology transactions, and IP strategy. He co-founded three startups, including Emmaus Life Sciences, a pharmaceutical company focused on sickle cell disease treatment, which he co-founded in 2000 and served as COO for 10 years.
KK
Kurt KrugerinExecutive
LT
Lan TranExecutive
YN
Yasushi NagasakiinExecutive
WC
Willis C. LeeinChief Executive Officer
Board
RD
Robert DickeyBoard director
MO
Masaharu OsatoBoard director
WP
Wei Peu ZenBoard director
IZ
Ian ZwickerBoard director
Reported raises · per SEC filings
Form D private placements$36.5M disclosed across 4 rounds · 2016–2019
▶$2.6MraisedApr 2019 · 7 investors · PharmaceuticalsRule 506(c)
▶$2.6MraisedApr 2019 · 7 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Yutaka NiiharaExecutive Officer, Director
- Kurt KrugerExecutive Officer
- Willis LeeExecutive Officer, Director
- Lan TranExecutive Officer
- Yasushi NagasakiExecutive Officer
- Robert DickeyDirector
- Masaharu OsatoDirector
- Wei Peu ZenDirector
- Ian ZwickerDirector
- Amount sold
- $2.6M
- Sales commissions
- $600K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$12.2MraisedNov 2018 · 18 investors · PharmaceuticalsRule 506(c)
▶$12.2MraisedNov 2018 · 18 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Yutaka NiiharaExecutive Officer, Director
- Masaharu OsatoDirector
- Willis LeeExecutive Officer, Director
- Wei Peu ZenDirector
- Robert DickeyDirector
- Lan TranExecutive Officer
- Kurt KrugerExecutive Officer
- Ian ZwickerDirector
- Yasushi NagasakiExecutive Officer
- Offering amount
- $12.2M
- Amount sold
- $12.2M
- Sales commissions
- $610K
- Placement agents
- T.R. Winston & Company, LLC
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$20MraisedOct 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$20MraisedOct 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lan T TranExecutive Officer
- Yutaka NiiharaExecutive Officer, Director
- Jon KuwaharaDirector
- Peter B LudlumExecutive Officer
- Ian ZwickerDirector
- Willis C LeeExecutive Officer, Director
- Yasushi NagasakiExecutive Officer
- Masaharu OsatoDirector
- Offering amount
- $20M
- Amount sold
- $20M
- Finders' fees
- $600K
- Proceeds to insiders
- $1M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedJan 2016 · PharmaceuticalsRule 506(b)
▶$1.7MraisedJan 2016 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jon KuwaharaDirector
- Willis C LeeExecutive Officer, Director
- Ian ZwickerDirector
- Lan T TranExecutive Officer
- Yutaka NiiharaExecutive Officer, Director
- Yasushi NagasakiExecutive Officer
- Masaharu OsatoDirector
- Peter B LudlumExecutive Officer
- Offering amount
- $40M
- Amount sold
- $1.7M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Medscape43 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Amicus Therapeutics33 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Agenus30 shared keywordsAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
World Health Organization, 202526 shared keywordsThe World Health Organization is a United Nations agency founded in 1948 that leads global health initiatives and emergency response across 194 member states. It works to expand universal health coverage, coordinate responses to health emergencies, and promote healthier lives across all life stages.
Companies competing with Emmaus Life Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does Emmaus Life Sciences do?
- Emmaus Life Sciences is a pharmaceutical company that develops and commercializes Endari (prescription-grade L-glutamine oral powder), an FDA-approved treatment for sickle cell disease, and pursues additional indications such as diverticulosis. The company sells and seeks marketing authorization for its products in the United States and internationally, including the Middle East and North Africa region.
- Who founded Emmaus Life Sciences?
- Emmaus Life Sciences was founded by Yutaka Niihara, Daniel R. Kimbell.
- How much funding has Emmaus Life Sciences raised?
- Emmaus Life Sciences has disclosed $36.5M raised across 4 rounds.
- Where is Emmaus Life Sciences headquartered?
- Emmaus Life Sciences is headquartered in Torrance, US.